#United States #Barrett's Esophagus #Castle Biosciences #TissueCypher #Friendwood

Transforming Barrett's Esophagus Management: The TissueCypher® Breakthrough Explained

In recent times, the realm of gastroenterological diagnostics has witnessed a significant advancement through the introduction of the TissueCypher® Barrett's Esophagus Test. A new study has highlighted its crucial role in tailoring management strategies for patients diagnosed with non-dysplastic Barrett's esophagus (NDBE). Conducted by Castle Biosciences, Inc. (Nasdaq: CSTL), this innovative approach has been shown to modify clinical recommendations in an impressive 90% of cases.

Unveiling the Study’s Insights

The study, titled The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett's Esophagus: A Case Series From a Gastrointestinal Surgery Center, was published in the prestigious Foregut: The Journal of the American Foregut Society. The research evaluated 30 patients at Keck Medical Center of the University of Southern California, analyzing how TissueCypher influenced their management post-test.

Dr. Caitlin C. Houghton, a board-certified foregut surgeon at USC and lead author of the study, emphasized, "Though all patients had a uniform diagnosis of non-dysplastic Barrett's, TissueCypher revealed varying levels of risk for progression among them. This differentiation allows us to personalize management strategies more effectively."

Key Findings and Their Importance

The results of the study clearly indicated the efficacy of TissueCypher in stratifying risk among patients with NDBE:

• - Risk Identification: The test identified that 17% of patients were at intermediate or high risk for progressing to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years, while the remaining 83% were classified as low risk.
• - Management Changes: All patients found to be at intermediate or high risk had their management plans escalated. This included recommendations for endoscopic eradication therapy for four patients and shorter surveillance intervals for one.
• - De-escalation for Low-Risk Patients: Notably, for the 84% of patients deemed low risk, management was adjusted accordingly, including extended surveillance intervals and cessation of endoscopic eradication therapy recommendations.
• - Increased Confidence Among Clinicians: In an impressive 97% of cases, TissueCypher results provided clinicians with heightened confidence in their management strategies.

These findings not only underscore the precision of risk assessment through TissueCypher but also highlight its potential to improve patient outcomes through more tailored treatment.

Significance of Barrett’s Esophagus

Barrett's esophagus is a condition marked by changes in the cells lining the esophagus, which can become precancerous. Traditionally, patients with NDBE have been viewed as low risk for progression; however, clinical experience shows that numerous factors can contribute to varying risks. This is where TissueCypher steps in as a game changer, bridging the gap for those who may require more vigilant surveillance or proactive measures.

Conclusion

As presented on September 27, 2026, at the American College of Surgeons Clinical Congress, the insights gained from the implementation of TissueCypher at the Keck Medical Center provide a powerful testament to the evolving landscape of gastroenterological care. With the backing of more than 17 peer-reviewed publications, TissueCypher continues to emerge as the leading independent predictor of progression, paving the way for improved patient management and outcomes.

For more information, visit Castle Biosciences’ website on the TissueCypher test and its implications in clinical practice. As we look to the future, innovations like this could reshape how we approach the diagnosis and management of precancerous conditions, ensuring a more personalized healthcare experience.